Cassava Sciences Inc
NASDAQ:SAVA

Watchlist Manager
Cassava Sciences Inc Logo
Cassava Sciences Inc
NASDAQ:SAVA
Watchlist
Price: 2.1 USD 4.48% Market Closed
Market Cap: 101.5m USD

Relative Value

There is not enough data to reliably calculate the relative value of SAVA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SAVA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.5
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-19.2
Industry
21.3
Forward
-5.1
vs History
vs Industry
Median 3Y
-12.5
Median 5Y
-16.8
Industry
16.7
vs History
vs Industry
Median 3Y
-11.8
Median 5Y
-15.4
Industry
24.7
vs History
93
vs Industry
70
Median 3Y
5.1
Median 5Y
6
Industry
2.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.1
vs History
3
vs Industry
56
Median 3Y
-8.5
Median 5Y
-10.7
Industry
12.8
vs History
3
vs Industry
53
Median 3Y
-8.4
Median 5Y
-10.5
Industry
16.3
Forward
0.4
vs History
3
vs Industry
57
Median 3Y
-10.7
Median 5Y
-14.2
Industry
14.9
vs History
3
vs Industry
43
Median 3Y
-10.1
Median 5Y
-12.5
Industry
18.2
vs History
vs Industry
7
Median 3Y
34.3
Median 5Y
35.6
Industry
1.9

Multiples Across Competitors

SAVA Competitors Multiples
Cassava Sciences Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cassava Sciences Inc
NASDAQ:SAVA
101.4m USD 0 -1.4 0.1 0.1
US
Eli Lilly and Co
NYSE:LLY
704.6B USD 14.4 63.4 34.1 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.1B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7 20.2 13.9 16
CH
Roche Holding AG
SIX:ROG
210.7B CHF 3.5 25.5 9.6 11.2
CH
Novartis AG
SIX:NOVN
185.7B CHF 4.2 17.6 10.4 13.9
UK
AstraZeneca PLC
LSE:AZN
164B GBP 4 28.4 130.9 197.3
US
Merck & Co Inc
NYSE:MRK
191B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
133.1B USD 2.1 16.9 7.3 10.3
P/E Multiple
Earnings Growth PEG
US
Cassava Sciences Inc
NASDAQ:SAVA
Average P/E: 25
Negative Multiple: -1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
63.4
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.5
32%
0.8
CH
Novartis AG
SIX:NOVN
17.6
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.4
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
17%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.9
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Cassava Sciences Inc
NASDAQ:SAVA
Average EV/EBITDA: 394.1
0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.1
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.9
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.2
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Cassava Sciences Inc
NASDAQ:SAVA
Average EV/EBIT: 1 697.3
0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.3
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
16
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
13.9
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.3
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1